Verifying Scientific Evidence Integrity

The scientific integrity space is fragmented across manual checks, post-hoc retractions, and ad-hoc vigilance. Researchers waste months building on retracted or manipulated papers, genomic analyses carry hidden reference bias that distorts pathogen surveillance, and clinicians in emerging disease regions lack structured guidance for unfamiliar conditions. No unified infrastructure exists to catch these integrity issues before they cascade into policy, meta-analyses, or patient care.

LLMs and computer vision have matured enough to analyze academic figures and detect manipulation patterns at scale, while automated citation tracking is now feasible. Simultaneously, retraction rates are accelerating and climate-driven range expansion of disease vectors is pushing tick-borne illnesses into regions where providers have no clinical experience.

Rough estimate: Combined TAM spans academic publishing integrity software, clinical decision support systems, and bioinformatics QC tooling, likely in the low single-digit billions globally. A solo founder could target a SAM of $50-100M by focusing on one vertical initially, with a realistic SOM of $1-5M within 2-3 years.